Patent US3975344A successfully refreshed from Google Patents.
US4348387A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and system for the controlled release of biologically active substances to a body fluid
Assignee: Rockefeller University
•
Filing: 1979-07-31
•
Granted: 1982-09-07
•
Expires: 1999-07-31
Abstract
Abstract A process and system for controlled delivery of a biologically active substance to an animal body fluid which comprises contacting fluid with a reversible complex of a conjugate (1) and a binding macromolecule (2), wherein the conjugate (1) comprises a biologically active portion which is intended to be proportionately released into a body fluid stream in response to varying concentration levels of a component of the body fluid stream, and a complexing substrate portion which conjugates with the biologically active portion and which is characterized by affinity to the binding macromolecule (2), competitively or non-competitively with the variable component of the body fluid; thereby causing the component present in the body fluid to complex to the binding macromolecule and thus releasing the conjugate (1) therefrom into the fluid. The process and system are particularly applicable for the glucose-controlled release of insulin and other hypoglycemic agents in the treatment of diabetes.
Inventors
- 👤 Michael Brownlee
- 👤 Anthony Cerami
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 10:02
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/6415; A61M; A61M31/00; A61M31/002; A61P; A61P3/00; A61P3/08
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
73 words
A process of treating hyperglycemia which comprises: delivering to a glucose containing human body fluid a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate (1); thereby causing the glucose present in said fluid to complex to said lectin and to release said conjugate into said fluid.
Claim 2
Dependent Claim
73 words
A process of treating hyperglycemia which comprises: delivering to a glucose containing human body fluid a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate (1); thereby causing the glucose present in said fluid to complex to said lectin and to release said conjugate into said fluid.
Claim 3
Dependent Claim
11 words
The process of claim 1 wherein said lectin is Concanavalin A.
Claim 4
Dependent Claim
10 words
The process of claim 1 wherein said carbohydrate is maltose.
Claim 5
Dependent Claim
21 words
The process of claim 1 wherein said reversible complex comprises at least two conjugates of different affinity towards said lectin (2).
Claim 6
Dependent Claim
19 words
The process of claim 1 wherein said reversible complex comprises at least two conjugates with different hypoglycemically active portions.
Claim 7
Dependent Claim
16 words
The process of claim 5 wherein said two different hypoglycemically active portions are guanosine and insulin.
Claim 8
Dependent Claim
19 words
The process of claim 1 wherein said carbohydrate is a manno-oligosaccharide containing from 2 to 7 (1→2) α-D-mannopyranosyl residues.
Claim 9
Dependent Claim
47 words
A controlled release medication which comprises: a hypoglycemically active amount of a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate.
Claim 10
Dependent Claim
47 words
A controlled release medication which comprises: a hypoglycemically active amount of a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate.
Claim 11
Dependent Claim
12 words
The medication system of claim 8 wherein said lectin is Concanavalin A.
Claim 12
Dependent Claim
11 words
The medication system of claim 8 wherein said carbohydrate is maltose.
Claim 13
Dependent Claim
22 words
The medication system of claim 8 wherein said reversible complex comprises at least two conjugates (1) having different affinity towards said lectin.
Claim 14
Dependent Claim
20 words
The medication system of claim 8 wherein said reversible complex comprises at least two conjugates with different hypoglycemically active portions.
Claim 15
Dependent Claim
20 words
The medication system of claim 8 wherein said carbohydrate is a manno-oligosaccharide containing from 2 to 7 (1→2) α-D-mannopyranosyl residues.
Claim 16
Dependent Claim
25 words
The process of claim 1 wherein said insulin/carbohydrate conjugate is such that not all three primary amino groups of insulin are substituted by said carbohydrate.
Claim 17
Dependent Claim
25 words
The medication of claim 8 wherein said insulin/carbohydrate conjugate is such that not all three primary amino groups of insulin are substituted by said carbohydrate.
References Cited (Backward Citations)
US4003792A
Cited
US3847890A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-09-06 | 1986-03-08 | 1986-09-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-09-06 | 1990-03-08 | 1990-09-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-09-06 | 1994-03-08 | 1994-09-07 | $7700.00 | Window Closed / Lapsed |